首页> 美国卫生研究院文献>Oncotarget >RAS testing and cetuximab treatment for metastatic colorectal cancer: a cost-effectiveness analysis in a setting with limited health resources

【2h】

RAS testing and cetuximab treatment for metastatic colorectal cancer: a cost-effectiveness analysis in a setting with limited health resources

机译：用于转移性结直肠癌的RAS测试和西妥昔单抗治疗：在卫生资源有限的情况下的成本效益分析

代理获取

本网站仅为用户提供外文OA文献查询和代理获取服务，本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文，但由于OA文献来源多样且变更频繁，仍可能出现获取不到、文献不完整或与标题不符等情况，如果获取不到我们将提供退款服务。请知悉。

获取外文期刊封面目录资料

页面导航

摘要
著录项
引文网络
相似文献
相关主题

摘要

PURPOSETo test the cost-effectiveness of cetuximab plus irinotecan, fluorouracil, and leucovorin (FOLFIRI) as first-line treatment in patients with metastatic colorectal cancer (mCRC) from a Chinese medical insurance perspective.

机译：目的从中国医疗保险的角度测试西妥昔单抗联合伊立替康，氟尿嘧啶和亚叶酸钙（FOLFIRI）作为转移性结直肠癌（mCRC）患者的一线治疗的成本效益。

著录项

期刊名称 Oncotarget
作者
Bin Wu; Yuan Yao; Ke Zhang; Xuezhen Ma;
展开▼
作者单位

展开▼
年(卷),期 2017(8),41
年度 2017
页码 71164–71172
总页数 9
原文格式 PDF
正文语种
中图分类肿瘤学;细胞生物学;
关键词
colorectal cancer cost-effectiveness cetuximab gene mutation;

机译：大肠癌;成本效益;西妥昔单抗;基因突变;

相似文献

外文文献
中文文献
专利

1. Cost-effectiveness analysis of cetuximab|[sol]|irinotecan vs active|[sol]|best supportive care for the treatment of metastatic colorectal cancer patients who have failed previous chemotherapy treatment [J] . N Starling, D Tilden, J White, British Journal of Cancer . 2007,第2期

机译：西妥昔单抗| [伊索] |伊立替康与主动| [索] |最佳支持治疗在先前化疗失败的转移性结直肠癌患者中的成本效益分析
2. Cost-effectiveness of cetuximab, cetuximab plus irinotecan, and panitumumab for third and further lines of treatment for KRAS wild-type patients with metastatic colorectal cancer [J] . HoyleM., PetersJ., CrathorneL., Value in health: the journal of the International Society for Pharmacoeconomics and Outcomes Research . 2013,第2期

机译：西妥昔单抗，西妥昔单抗加伊立替康和帕尼单抗用于KRAS野生型转移性结直肠癌患者第三线及其他治疗的成本效益
3. Treatment sequence with either irinotecan/cetuximab followed by FOLFOX-4 or the reverse strategy in metastatic colorectal cancer patients progressing after first-line FOLFIRI/bevacizumab: An Italian Group for the Study of Gastrointestinal Cancer phase III, randomised trial comparing two sequences of therapy in colorectal metastatic patients [J] . European journal of cancer: official journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR) . 2017,第期

机译：用伊立替康/西替昔单抗的治疗序列，然后进行Folfox-4或转移性结肠直肠癌患者的反向策略，在第一线Folfiri / Bevacizumab后进展：用于研究胃肠癌期III的意大利组，随机试验比较两种治疗序列结肠直肠转移性患者
4. Embedded system for a battery-operated LED-based photodynamic therapy device for treatment of early-stage oral cancers in resource-limited settings [C] . Liam Daly, Grant Rudd, Hui Liu, International Conference on Bio-engineering for Smart Technologies . 2017

机译：基于电池的基于LED的光动力疗法设备的嵌入式系统，用于在资源有限的环境中治疗早期口腔癌
5. Cervical Cancer in Low-Income Settings: Costs, Cost-effectiveness, and Budget Impact of Integrating Screening and Treatment into Existing Health Systems in East Africa [D] . Vodicka, Elisabeth. 2018

机译：低收入地区的宫颈癌：将筛查和治疗纳入东非现有卫生系统的费用，成本效益和预算影响
6. Economic Evaluation of First-Line Treatments for Metastatic Renal Cell Carcinoma: A Cost-Effectiveness Analysis in A Health Resource–Limited Setting [O] . Bin Wu, Baijun Dong, Yuejuan Xu, 2009

机译：一线治疗转移性肾细胞癌的经济评价：健康资源有限环境下的成本-效果分析
7. PRM93 Validation of A Global Economic Model to Evaluate The Cost-Effectiveness Of Targeted Treatments Using Companion Diagnostics In Advanced/Metastatic Cancer Treatment Using Kras Testing For Cetuximab Therapy In Metastatic Colorectal Cancer [O] . Mathurin K., Beauchemin C., Lachaine J. 2014

机译：PRM93验证了一种全球经济模型，以评估针对性疗法的成本-效果，该疗法在伴随/诊断转移性结直肠癌中使用克拉斯检验的西妥昔单抗疗法用于晚期/转移性癌症治疗中的伴随诊断

RAS testing and cetuximab treatment for metastatic colorectal cancer: a cost-effectiveness analysis in a setting with limited health resources

摘要

著录项

引文网络

相似文献

相关主题

期刊订阅